WallStSmart

Agnico Eagle Mines Limited (AEM)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 368% more annual revenue ($63.32B vs $13.54B). AEM leads profitability with a 39.5% profit margin vs 11.8%. PFE appears more attractively valued with a PEG of 13.77. AEM earns a higher WallStSmart Score of 75/100 (B+).

AEM

Strong Buy

75

out of 100

Grade: B+

Growth: 10.0Profit: 9.5Value: 4.7Quality: 8.5
Piotroski: 6/9Altman Z: 2.83

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AEMOvervalued (-12.6%)

Margin of Safety

-12.6%

Fair Value

$192.97

Current Price

$193.21

$0.24 premium

UndervaluedFair: $192.97Overvalued
PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AEM6 strengths · Avg: 9.8/10
Profit MarginProfitability
39.5%10/10

Keeps 40 of every $100 in revenue as profit

Operating MarginProfitability
62.8%10/10

Strong operational efficiency at 62.8%

Revenue GrowthGrowth
66.1%10/10

Revenue surging 66.1% year-over-year

EPS GrowthGrowth
108.6%10/10

Earnings expanding 108.6% YoY

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Market CapQuality
$93.89B9/10

Large-cap with strong market position

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

AEM1 concerns · Avg: 2.0/10
PEG RatioValuation
28.152/10

Expensive relative to growth rate

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : AEM

The strongest argument for AEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 39.5% and operating margin at 62.8%. Revenue growth of 66.1% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : AEM

The primary concerns for AEM are PEG Ratio.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

AEM profiles as a growth stock while PFE is a value play — different risk/reward profiles.

AEM carries more volatility with a beta of 0.57 — expect wider price swings.

AEM is growing revenue faster at 66.1% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

AEM scores higher overall (75/100 vs 55/100), backed by strong 39.5% margins and 66.1% revenue growth. PFE offers better value entry with a 29.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agnico Eagle Mines Limited

BASIC MATERIALS · GOLD · USA

Agnico Eagle Mines Limited is engaged in the exploration, development and production of mineral properties in Canada, Sweden and Finland. The company is headquartered in Toronto, Canada.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?